Related Experiment Videos
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
J Astermark1, P Petrini, L Tengborn
1Department for Coagulation Disorders, University of Lund, University Hospital, Malmö.
Insights
Starting prophylactic treatment for severe hemophilia (a bleeding disorder) before age three significantly improves long-term joint health. Early intervention is key, though treatment regimens can be individualized.
Area of Science:
- Hematology
- Orthopedics
- Pediatric Medicine
Background:
- Severe hemophilia requires lifelong management to prevent joint damage.
- Prophylactic treatment with clotting factor concentrates is standard care.
- Optimal timing and intensity of prophylaxis remain areas of investigation.
Purpose of the Study:
- To evaluate the impact of early prophylactic treatment initiation on joint bleeds and orthopedic outcomes in severe hemophilia.
- To compare different prophylactic infusion frequencies.
- To identify predictors for arthropathy development.
Main Methods:
- Retrospective analysis of 121 severe hemophilia patients on weekly prophylactic factor concentrates.
- Subgroup analysis based on age at treatment initiation (before 3, 3-5, 6-9 years).
- Comparison of once-weekly vs. more intensive infusion regimens (2-3 times/week).
Main Results:
- Starting prophylaxis before age 3 significantly improved outcomes compared to later initiation.
- Shortening infusion intervals reduced the overall annual number of joint bleeds.
- Age at prophylaxis initiation was an independent predictor of arthropathy; dose and initial interval were not.
Conclusions:
- Early initiation of prophylactic factor replacement therapy, ideally before age 3, is crucial for preventing arthropathy in severe hemophilia.
- Treatment regimens can be individualized based on bleeding patterns.
- The need for venous access systems should be assessed individually.
Abstract:
The frequency of joint bleeds and orthopaedic joint scores were evaluated in 121 patients with severe haemophilia who had started prophylactic treatment with clotting factor concentrates at least once weekly before the age of 10. 75 of the patients started before the age of 3, 31 at the age of 3-5 and 15 at the age of 6-9. Each subgroup was evaluated separately. In addition, a regimen of one infusion weekly was compared with that of two (haemophilia B) or three (haemophilia A) infusions weekly in each patient. A significant decrease in the overall number of joint bleeds per year was found after shortening the infusion interval (P<0.005), but the individual bleeding pattern varied. In survival analysis of the first pathologic joint score event, those who started prophylaxis before the age of 3 had a better outcome overall than those starting at later ages (P=0.001). However, in subgroup analysis, no significant difference was seen in the annual number of joint bleeds and the development of arthropathy between those starting with, or shifting to, the more intensive regimen before the age of 3 and those that were put on this regimen at the age of 3-5. Age at start of prophylaxis was found to be an independent predictor for the development of arthropathy (P=0.0002), whereas dose and infusion interval at start were not. Our data emphasize the importance of starting replacement therapy during the first years of life. However, it seems that when beginning the regimen it can be individualized and adjusted according to the bleeding pattern. In this way, the need for a venous access system may be assessed on an individual basis.